A Phase II study of salvage high-dose-rate brachytherapy for the treatment of locally recurrent prostate cancer after definitive external beam radiotherapy Journal Article


Authors: Yamada, Y.; Kollmeier, M. A.; Pei, X.; Kan, C. C.; Cohen, G. N.; Donat, S. M.; Cox, B. W.; Zelefsky, M. J.
Article Title: A Phase II study of salvage high-dose-rate brachytherapy for the treatment of locally recurrent prostate cancer after definitive external beam radiotherapy
Abstract: Purpose: We report the toxicity and biochemical tumor control outcome of a prospective Phase II study using high-dose-rate brachytherapy (HDR) alone as a salvage therapy for recurrent disease after external beam radiotherapy (EBRT). Methods: Forty-two patients with biopsy-proven recurrence were enrolled on a Phase II study of salvage HDR monotherapy using iridium-192. Median pretreatment EBRT dose was 8100cGy (6840-8640cGy) and the median time from completion of EBRT to salvage HDR was 73 months. The protocol prescription dose of 3200cGy was delivered in four fractions over 30 hours in a single insertion. Median followup after salvage HDR was 36 months (6-67 months). Results: The actuarial prostate-specific antigen biochemical relapse-free survival and distant metastases-free survival rates at 5 years were 68.5% and 81.5%, respectively. Cause-specific survival was 90.3%. Late genitourinary Grade 1and 2 toxicities were found in 38% and 48%, respectively, and one patient developed Grade 3 urinary incontinence. Late Grade 1 and 2 gastrointestinal toxicity was noted in 17% and 8% of patients, respectively. Three patients (7%) developed Grade 2 late urinary toxicity (urethral stricture), which were corrected with urethral dilatation, and one patient developed Grade 3 urinary incontinence. No Grade 4 toxicities were observed. Conclusions: Genitourinary toxicity was the most commonly encountered toxicity observed after salvage HDR but severe toxicities were uncommon. Salvage HDR is an effective and well-tolerated modality for locally recurrent prostate cancer and should be considered even for patients who have previously been treated with ultra-high dose levels of EBRT. © 2014 American Brachytherapy Society.
Keywords: salvage brachytherapy; high dose rate brachytherapy
Journal Title: Brachytherapy
Volume: 13
Issue: 2
ISSN: 1538-4721
Publisher: Elsevier Science, Inc.  
Date Published: 2014-03-01
Start Page: 111
End Page: 116
Language: English
DOI: 10.1016/j.brachy.2013.11.005
PROVIDER: scopus
PUBMED: 24373762
PMCID: PMC5718052
DOI/URL:
Notes: Export Date: 2 April 2014 -- CODEN: BRACC -- Source: Scopus
Altmetric Score
MSK Authors
  1. Brett Wayne Cox
    63 Cox
  2. Michael J Zelefsky
    655 Zelefsky
  3. Sherri M Donat
    135 Donat
  4. Yoshiya Yamada
    374 Yamada
  5. Gilad N Cohen
    139 Cohen
  6. Marisa A Kollmeier
    158 Kollmeier
  7. Chu-Cheng Kan
    7 Kan
  8. Xin Pei
    104 Pei